

Light-responsive in situ hydrogel for intraocular drug delivery

Domain: Therapeutics

About Technology: This technology involves a UV-triggered intravitreal gel depot designed for sustained drug release, minimizing injection frequency in chorioretinal conditions and providing a promising alternative for patients unresponsive to anti-VEGF therapy

Intended Use: Spironolactone-loaded, long-acting, light-responsive in situ hydrogel: a novel therapy beyond anti-VEGF for treating diabetic retinopathy



Advantages:

- Enables up to 90 days of sustained drug release with enhanced biocompatibility, Reduces injection frequency
- Improves safety and patient adherence

Development Status: Preclinical studies completed

Institute(s): Department of Pharmacy, Birla Institute of Technology and Sciences (BITS), Hyderabad Campus

Inventor(s): Prof. Nirmal Jayabalan, Sai Shreya Cheruvu

For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in